Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Algernon Pharmaceuticals is a clinical stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough. The company's business model is highly capital efficient and strives to deliver maximum shareholder value. Algernon's unique approach to drug discovery is based on the concept of drug repurposing.

Recent & Breaking News (CSE:AGN)

Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat NASH and NAFLD

GlobeNewswire 10 days ago

Pharmaceutical microcap penny stock is up big after asset sale

Trevor Abes  November 22, 2023

Algernon Pharmaceuticals Announces LOI for the Acquisition of its Chronic Cough Research Program by U.S. Based Seyltx for USD $2M and a 20% Equity Position

GlobeNewswire November 22, 2023

Algernon Pharmaceuticals Receives Japanese Patent Notice of Allowance for Treatment of NASH with Repirinast

GlobeNewswire November 8, 2023

Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

GlobeNewswire September 6, 2023

Algernon to begin Phase 2 psychedelic drug DMT stroke study

Jonathon Brown August 8, 2023

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

GlobeNewswire August 8, 2023

Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

GlobeNewswire July 14, 2023

Algernon explores spin-off potential of chronic cough drug program

Jonathon Brown June 27, 2023

Algernon Pharmaceuticals Engages Maxim Group to Explore Spin-Off of its Ifenprodil Phase 2 Chronic Cough Drug Development Program

GlobeNewswire June 27, 2023

Canadian health care stock to report update on cough treatment study

Jonathon Brown June 6, 2023

Algernon Pharmaceuticals to Present Phase 2 Ifenprodil Cough Data at the 2023 American Cough Conference

GlobeNewswire June 6, 2023

Algernon completes Phase 1 DMT trial for brain injury treatment

Jonathon Brown June 5, 2023

Algernon NeuroScience Announces Successful Completion of Highest Planned Single Dose in DMT Phase 1 Trial; Accelerates Plans for Phase 2 Stroke and TBI Studies

GlobeNewswire June 5, 2023

Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

GlobeNewswire May 31, 2023

Algernon Pharmaceuticals Announces Closing of Rights Offering

GlobeNewswire May 5, 2023

CSE Bulletin: Expiry - Algernon Pharmaceuticals Inc. - Rights (AGN.RT)

Newsfile April 21, 2023

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching Cut Off Date and Time

GlobeNewswire April 20, 2023

Algernon Pharmaceuticals Announces Notice of Allowance for Method of Use U.S. Patent Application

GlobeNewswire April 17, 2023

Algernon (CSE:AGN) sees successful dosing of second cohort

Jonathon Brown April 4, 2023